Matt Kalaycio named chair of board of directors at NCCN

Matt Kalaycio was named chair of the board of directors at the National Comprehensive Cancer Network. Christopher H. Lieu was elected as vice chair, succeeding Kalaycio in the position he has held since 2022.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

DOWNLOAD THE PDF

Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Investigational Orca-T treatment for hematologic malignancies meets primary endpoint in phase III trial

Orca Bio, a late-stage biotechnology company, on March 17 announced results from the pivotal phase III Precision-T study of Orca-T, its lead investigational allogeneic T-cell immunotherapy, in patients with acute myeloid leukemia, acute lymphoblastic leukemia, high-risk myelodysplastic syndrome and mixed-phenotype acute leukemia. Orca-T is manufactured using highly purified regulatory T-cells, hematopoietic stem cells and conventional T-cells derived from peripheral blood from either related or unrelated matched donors.

March 28, 2025

Vol.51 No.12

Accelerating translational research in leukemia: The City of Hope approach

As a physician-scientist, I navigate the intersection of laboratory research and clinical care every day. At City of Hope, our mission is to rapidly translate groundbreaking discoveries into effective treatments for patients with hematologic malignancies, particularly acute leukemias. This is possible due to a unique combination of infrastructure and culture combined with an unwavering sense of urgency.

Florida leukemia rates rising rapidly as population ages, study shows

Driven by a steady influx of retirees, Florida now has the highest leukemia rates of any U.S. state and the disease is the fastest-rising cancer type statewide, according to research from Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

March 14, 2025

Vol.51 No.10

Guest Editorial

World Cancer Day 2025: A symbol of personal and collective uncertainty

My entire life I was told to respectfully question anything and everything, because questions equal answers, which provide understanding and thereby comfort—even with the uncomfortable. It’s simply in my DNA.

February 07, 2025

Vol.51 No.05

By Ruth Fein Revell

Clinical Trials & Tribulations

LLS former CSO: Immunotherapy, precision medicine redefined blood cancer treatment

As the chief scientific officer of the Leukemia & Lymphoma Society for the past eleven years, it has been a privilege to lead a group of scientists that has doled out more than $600 million for cutting-edge hematologic oncology research. These dollars went to more than 1,000 research projects through initiatives like our biomedical research grant programs and LLS’s venture philanthropy, the Therapy Acceleration Program (TAP).

NCCN publishes patient resource on genetic testing to guide patient decisionmaking

The National Comprehensive Cancer Network published its first patient resource aimed at informing people about the latest recommendations around hereditary and familial cancer risk. The document provides guidance on testing for inherited genetic mutations that can raise the risk of cancer.

January 17, 2025

Vol.51 No.02

By Jacquelyn Cobb